Search

Displaying results 6491 - 6500 of 10000 in total
  1. Drug

    Trabedersen

    go.drugbank.com/drugs/DB05697
    Investigational

  2. Drug

    Selamectin

    go.drugbank.com/drugs/DB11459
    ExperimentalVet approved

    as prevent heartworms, fleas, ear mites, hookworms, and roundworms in cats. … Selamectin is a topical parasiticide and antihelminthic used on dogs and cats to treat and prevent infections of heartworms, fleas, ear mites, sarcoptic mange, and certain types of ticks in dogs as well

  3. Drug

    Repinotan

    go.drugbank.com/drugs/DB06506
    Investigational

    Repinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.

  4. Drug

    Descartes-30

    go.drugbank.com/drugs/DB16361
    Investigational

    Descartes-30 is an RNA-engineered off-the-shelf allogeneic mesenchymal stem cell (MSC) product developed by Cartesian Therapeutics.

  5. Drug

    Chikungunya virus Senegal strain 37997 envelope protein E1

    go.drugbank.com/drugs/DB21767
    ApprovedInvestigational

    One of three components of a recombinant Chikungunya virus vaccine called Vimkunya.

    Synonyms: Chikungunya virus Senegal strain 37997 envelope protein E1
  6. Drug

    Biricodar

    go.drugbank.com/drugs/DB04851
    Investigational

    The pipecolinate derivative biricodar (VX-710) is a clinically applicable modulator of P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1).

  7. Drug

    MLN3897

    go.drugbank.com/drugs/DB06505
    Experimental

    MLN3897, a novel CCR1 inhibitor, disrupts osteoclast formation and blocks the interaction between multiple myeloma cells and osteoclasts.

  8. Drug

    Telavancin

    go.drugbank.com/drugs/DB06402
    ApprovedInvestigational

    MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others.

  9. Drug

    Edivoxetine

    go.drugbank.com/drugs/DB09184
    Investigational

    Edivoxetine failed to be approved for major depressive disorder after phase III clinical trials in 2012. … Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant

  10. Drug

    R-851

    go.drugbank.com/drugs/DB05747
    Experimental

    R-851 is part of the family of immune response modifier (IRM) and it acts in a novel way to stimulate the human body's immnune system to attack virus-infected cells and tumor cells.